Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptal1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 4	APR 07	STN is raising the limits on saved answers
NEWS 5	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 7	APR 28	CAS patent authority coverage expanded
NEWS 8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS 10	MAY 08	STN Express, Version 8.4, now available
NEWS 11	MAY 11	STN on the Web enhanced
NEWS 12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS 13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS 14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS 15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS 16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS 17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS 18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS 19	JUN 29	EPFULL adds SLART to AB, MCLM, and TI fields

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:13:51 ON 29 JUN 2009

-> file reg

	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	0.22	0.22

10/519,979

```
FILE 'REGISTRY' ENTERED AT 12:14:15 ON 29 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 JUN 2009  HIGHEST RN 1160218-33-6
DICTIONARY FILE UPDATES:  28 JUN 2009  HIGHEST RN 1160218-33-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10519979d.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=>
Uploading C:\Program Files\Stnexp\Queries\10519979c.str

L2      STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 12:15:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      111 TO ITERATE

100.0% PROCESSED      111 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1588 TO     2852
PROJECTED ANSWERS:               0 TO        0

L3            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:15:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2534 TO ITERATE

100.0% PROCESSED     2534 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01
```

```
L4            4 SEA SSS FUL L1

-> s l2
SAMPLE SEARCH INITIATED 12:15:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      111 TO ITERATE

100.0% PROCESSED      111 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1588 TO     2852
PROJECTED ANSWERS:                0 TO        0

L5            0 SEA SSS SAM L2

-> s l2 full
FULL SEARCH INITIATED 12:15:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2534 TO ITERATE

100.0% PROCESSED     2534 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

L6            5 SEA SSS FUL L2

-> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                ENTRY     SESSION
FULL ESTIMATED COST                            371.76     371.98

FILE 'CAPLUS' ENTERED AT 12:15:36 ON 29 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Jun 2009  VOL 151 ISS 1
FILE LAST UPDATED: 28 Jun 2009  (20090628/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Apr 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Apr 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

-> s l4 or l6
             4 L4
             9 L6
L7          10 L4 OR L6

=> d bib abs hitstr 1-10 l7

L7   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2009:506801  CAPLUS
DN   150:563497
TI   Concise Synthesis of Chafurosides A and B
```

AU Furuta, Takumi; Nakayama, Miho; Suzuki, Hirotaka; Tajimi, Hiroko; Inai, Makoto; Nukaya, Haruo; Wakimoto, Toshiyuki; Kan, Toshiyuki
CS School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan
SO Organic Letters (2009), 11(11), 2233-2236
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
GI



I



II

AB The regioselective synthesis of chafurosides A (I) and B (II) from a same Me ketone was accomplished using a novel protecting group strategy. Both flavone rings were constructed from a β-diketone intermediate, which was readily obtained by condensation of an acyl donor and the Me ketone. Construction of the dihydrofuran ring was achieved via an intramol. Mitsunobu reaction.
IT 720684-57-1P 866737-00-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of chafurosides A and B)
RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 866737-00-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1216881 CAPLUS
DN 149:402106
TI Novel preparation of chafuroside based on efficient construction of flavones
IN Suga, Toshiyuki; Furuta, Takumi
PA University of Shizuoka, Japan
SO Jpn. Kokai Tokkyo Koho, 13pp.
CODEN: JKXXAF
DI Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2008239513	A	20081009	JP 2007-79311	20070326
PRAI JP 2007-79311		20070326		

OS MARPAT 149:402106
GI



AB Chafuroside (I), already known as anti-inflammatory agent isolated from oolong tea, is prepared by treatment of compds. II [R1 = (protected) OH, ether residue, ester residue, halo; R2 = H, alkyl, acyl, (protected) OH, halo, glucose or other sugar residue] with compds. III [R3 = H, alkyl, acyl, (protected) OH, halo; R4 = benzotriazolyl, imidazolyl, halo, ester

residue] in the presence of bases in aprotic solvents, treatment of the resulting compds. IV [R5 = H, alkyl, acyl, (protected) OH, halo; R6 = (protected) OH, ether residue, ester residue, halo; R7 = H, alkyl, acyl, (protected) OH, halo, glucose or other sugar residue] in the presence of acids in protic or aprotic solvents, then treatment of the obtained compds. V [R8 = H, alkyl, acyl, (protected) OH, halo; R9 = (protected) OH, ether residue, ester residue, halo; R10 = H, alkyl, acyl, (protected) OH, halo, glucose or other sugar residue] with azodicarboxamides or azodicarboxylate esters, and trialkylphosphines or triarylphosphines, or in the presence of phosphoranes in aprotic solvents. Thus, 1-[2,4-bis(benzyloxy)-6-(tert-butyldiphenylsilyloxy)-3-((2S,3R,5R)-3,4,5-tris(benzyloxy)-6-benzyloxymethyltetrahydro-2H-pyran-2-yl)phenyl]ethanone was reacted with 1H-benzo[d][1,2,3]triazol-1-yl(4-benzyloxyphenyl)methanone at -78° for 1.5 h in the presence of KHMDS/MePh in THF to give the corresponding β-diketone with 48% yield, which was deprotected with TBAF in THF, cyclized in the presence of p-TsOH, debenzylated, and treated with PPh3/THF and DEAD to afford I.

IT 720684-57-1P, Chafuroside
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of chafuroside via β-diketones)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:1332639 CAPLUS

DN 146:420984

TI Antitumors isolated from oolong tea leaf

IN Wakabayashi, Keiji; Nukatani, Haruo; Muto, Tomohiro

PA National Cancer Center, Japan

SO Jpn. Kokai Tokkyo Koho, 18pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2006342103	A	20061221	JP 2005-169262	20050609
PRAI JP 2005-169262		20050609		

AB The antitumoric OTAC (Oolong tea active compound), flavone derivs., are extracted from Oolong tea leaf. The antitumoric OTAC are able to inhibit cancer in rat colonic aberrant crypt foci (ACF model) and colonic polyp-formation Apc gene-deficient mouse model. Extraction of the antitumoric OTAC from the oolong tea leaf with hot water and inhibition of cancer in the two animal models were shown.

IT 720684-57-1P 866737-00-0P
RL: FFD (Food or feed use); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(OTAC antitumors isolated from oolong tea leaf)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 866737-00-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:441728 CAPLUS
DN 145:347946
TI Inhibition of intestinal carcinogenesis by a new flavone derivative, Chafuroside, in oolong tea
AU Niho, Naoko; Mutoh, Michihiro; Sakano, Katsuhisa; Takahashi, Mami; Hirano, Sachiko; Nukaya, Haruo; Sugimura, Takashi; Wakabayashi, Keiji
CS Cancer Prevention Basic Research Project, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
SO Cancer Science (2006), 97(4), 248-251
CODEN: CSACCM; ISSN: 1347-9032
PB Blackwell Publishing Asia Pty Ltd.
DT Journal
LA English
AB A new flavone derivative, Chafuroside, has been isolated as a strong anti-inflammatory compound from oolong tea leaves, and its structure determined to be (2R,3S,4S,4aS,11bS)-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-3,4,4a,11b-tetrahydro-2H,10H-pyrano[2',3':4,5]furo[3,2-g]chromen-10-one. To assess its potential to inhibit intestinal carcinogenesis, 2.5, 5, and 10 ppm Chafuroside was given in the diet to Apc-deficient Min mice for 14 wk from 6 wk of age. Total nos. of polyps were reduced to 83, 73,and 56% of the control value, resp. Moreover, dietary administration at 10 and 20 ppm reduced azoxymethane (AOM)-induced colon aberrant crypt foci (ACF) development in rats to 69% of the AOM-treated control value with the higher dose. Chafuroside-associated toxicity was not observed at 2.5-10 ppm in Min mice and 10-20 ppm in AOM-treated rats. These results suggest that Chafuroside might be a good chemopreventive agent for colon cancer.
IT 720684-57-1, Chafuroside
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of intestinal carcinogenesis by Chafuroside in oolong tea)

RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:36756 CAPLUS
DN 144:108139
TI Preparation of flavones, their medial compositions, and their use as antiallergy and anti-inflammatory agents
IN Nakatsuka, Takashi; Nimura, Junko
PA Daiichi Asbio Pharma Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2006008626	A	20060112	JP 2004-190367	20040628
PRAI JP 2004-190367		20040628		

OS MARPAT 144:108139
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Flavones I [R1a-R1e = H, OH, C1-6 linear or branched alkyl(oxy), halo] and their their pharmacol. acceptable salts are prepared from p-azidobenzyloxyfluoropyrans II (R3a-xiro = protecting group) and 2-hydroxyacetophenones III (R3d, R3e = protecting group) in the presence of lewis acids via IV (R3a-R3e = protecting group; R3f = p-nitrobenzyl, p-azidobenzyl). Thus, cyclization of 8-[(2S,3S,4R,5R,6R)-4,5-bis(benzyloxy)-6-benzyloxymethyl-3-hydroxytetrahydro-2H-pyran-2-yl]-5,7-dihydroxy-2-phenyl-4H-chromen-4-one gave [7aS,8S,9S,10S,11aS)-8,9-bis(benzyloxy)-10-(benzyloxy)methyl-5-hydroxy-2-phenyl-7a,9,10,11a-tetrahydro-4H,8H-pyrano[2',3':4,5]furo[2,3-h]chromen-4-one, which was deprotected to afford the corresponding flavone derivative The product inhibited the ear swelling of in mice with TNCB-induced contact dermatitis in a dose-dependent manner.
IT 866737-00-0P 873077-63-5P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of flavones as antiallergy and anti-inflammatory agents)
RN 866737-00-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 873077-63-5 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-methoxyphenyl)-, (7aS,8S,9S,10R,11aS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 873077-34-0P 873077-51-1P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of flavones as antiallergy and anti-inflammatory agents)
RN 873077-34-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5-hydroxy-2-(4-hydroxyphenyl)-8,9-bis(phenylmethoxy)-10-[(phenylmethoxy)methyl]-, (7aS,8S,9R,10R,11aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 873077-51-1 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5-hydroxy-2-(4-methoxyphenyl)-8,9-bis(phenylmethoxy)-10-[(phenylmethoxy)methyl]-, (7aR,8S,9R,10R,11aS)- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1196260 CAPLUS
DN 143:440151
TI Preparation of flavone C glycoside
IN Tsuji, Kunio; Tanaka, Kei; Nukatani, Haruo; Furuta, Takumi
PA Japan Science and Technology Agency, Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005314260	A	20051110	JP 2004-132592	20040428
PRAI JP 2004-132592		20040428		

OS MARPAT 143:440151
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compound I, which was isolated as antiallergy agent from oolong tea

extract, is prepared by condensation of resorcinols II [R1, R2 = H, protecting group; R3 = (protected) OH, ether group, ester group; R4 = H, CO; when R3 = ether group and R4 = CO; then R3R4 may form (un)substituted ring] with sugars III (R5 = H, protecting group; R6 = halo, OC:NHCX3; X = halo) in the presence of Lewis acid catalysts in aprotic solvents and by treatment of C glycosides IV (R7, R8 = similar group as in R1, R2; R9, R10 = similar group as in R3, R4) with azodicarboxamide or azodicarboxylate esters and trialkylphosphine, triarylphosphine, or phosphoranes in aprotic solvents. Thus, 4-benzyloxy-2,6-dihydroxyacetophenone was treated with O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyloxy)trichloroacetimidate in the presence of TMSOTf in CH2Cl2, esterified with 4-methoxymethoxybenzoic acid, cyclized, debenzylated, treated with TMAD and Bu3P in THF, and deprotected to give I.

IT 791601-83-7P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of flavone C glycoside from resorcinols and sugars)

RN 791601-83-7 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-[4-(methoxymethoxy)phenyl]-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-57-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of flavone C glycoside from resorcinols and sugars)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:1103788 CAPLUS

DN 143:386847

TI Process for producing flavone c glycoside derivatives

IN Tsuji, Kuniro; Nukaya, Haruo

PA Suntory Limited, Japan

SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2005095416 A1 20051013 WO 2005-JP5695 20050328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
JP 2005289888 A 20051020 JP 2004-107760 20040331
CA 2561401 A1 20051013 CA 2005-2561401 20050328
EP 1731522 A1 20061213 EP 2005-721621 20050328
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 1938318 A 20070328 CN 2005-80010604 20050328
BR 2005009028 A 20070807 BR 2005-9028 20050328
SG 151297 A1 20090430 SG 2009-1982 20050328
KR 20070099597 A 20071118 KR 2006-719986 20060927
US 20080242855 A1 20081002 US 2008-593743 20080612
PRAI JP 2004-107760 A 20040331
WO 2005-JP5695 W 20050328

GI



I



II

AB This invention provided a process for efficiently producing a flavone C glycoside derivative represented by the formula I which is an antiallergic substance or its salt, or a flavone C glycoside derivative represented by the formula II or its salt. I and II can be easily and efficiently synthesized by using isovitexin and vitexin contained in herbs and so on as the starting materials reacted in the presence of dehydrating agent, such as 1,1'-azobis[N,N-dimethylformamide] and tri-n-butylphosphine.

IT 720684-57-1P 866737-00-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of flavone c glycoside derivs. by cyclization of (iso)vitexin)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 866737-00-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one,
7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:902389 CAPLUS
DN 141:380099
TI Flavone derivatives and process for producing them
IN Nakatsuka, Takashi
PA Daiichi Suntory Pharma Co., Ltd., Japan; Daiichi Suntory Biomedical Research Co., Ltd.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004092180	A1	20041028	WO 2004-JP5451	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2006176407	A	20060706	JP 2003-113976	20030418
PRAI JP 2003-113976	A	20030418		
OS MARPAT 141:380099				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for the production of flavone derivs. I [R1a, R1b, R1c, R1m and R1n = H, OH, etc.], intermediates for the production thereof; and processes for producing the intermediates were disclosed. Further, the invention provides compds. I [R1a, R1b, R1c, R1m and R1n = H, OH, etc.], (with the proviso that the compound wherein R1c is OH, R1a, R1b, R1m, and R1n are hydrogen, and the sugar moiety is D-mannose is excepted), pharmacol. acceptable salts thereof, and pharmaceutical compns. containing both. For example, treatment of a mixture of compound II, III (35 mg), e.g., prepared from Me 3,4,5-tri-O-benzyl-2-O-p-nitrobenzyl-D-glucopyranoside in 10 steps, with trimethylsilyl triflate at room temperature for 10 min afforded compound IV [R1a = R1b = R1c = R1m = R1n = H] (8 mg), converted to compound I [R1a = R1b = R1c = R1m = R1n = H] using BCl3. In contact dermatitis control test, compound I [R1a = R1b = R1c = R1m = R1n = H] exhibited p<0.05 (Dunnett's test) at ≥2 μg/kg dose. Disclosed compds. I are claimed useful for the treatment of inflammation, allery. Formulation is given.

IT 780789-07-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(flavone scaffold preparation using iodobenzene diacetate)

RN 780789-07-3 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-8-(4-methoxyphenyl)-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-, (2R,3R,4S,4aR,11bS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-64-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(flavone scaffold preparation via heterocyclization using trimethylsilyl triflate)

RN 720684-64-0 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-8-[4-(phenylmethoxy)phenyl]-, (2R,3R,4S,4aR,11bS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-57-1P 780789-12-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of flavone derivs. for treatment of inflammation, allergy)

RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 780789-12-0 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-methoxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:769344 CAPLUS
DN 141:411155
TI Concise total synthesis of flavone C-glycoside having potent anti-inflammatory activity
AU Furuta, Takumi; Kimura, Tomoyuki; Kondo, Sachiko; Mihara, Hisashi; Wakimoto, Toshiyuki; Nukaya, Haruo; Tsuji, Kuniro; Tanaka, Kiyoshi
CS School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 422-8526, Japan
SO Tetrahedron (2004), 60(42), 9375-9379
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 141:411155
AB The total synthesis of anti-inflammatory active flavone C-glycoside isolated from oolong tea extract is achieved. Introducing a C-glucosyl moiety to an aryl system and constructing a fused tetracyclic ring characteristic to this natural product were conducted based on the O-to-C rearrangement of sugar moiety and the successive intramol. Mitsunobu reaction, resp. This concise and efficient synthetic pathway is applicable to the large-scale synthesis of target flavone and for constructing a large library of related compds.
IT 791601-83-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of the anti-inflammatory active flavone C-glycoside isolated from oolong tea extract via rearrangement and intramol. Mitsunobu reaction)
RN 791601-83-7 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-[4-

{methoxymethoxy}phenyl]-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-57-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of the anti-inflammatory active flavone C-glycoside isolated from oolong tea extract via rearrangement and intramol. Mitsunobu reaction)
RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:403848 CAPLUS
DN 141:106296
TI First total synthesis of structurally unique flavonoids and their strong anti-inflammatory effect
AU Nakatsuka, Takashi; Tomimori, Yoshiaki; Fukuda, Yoshiaki; Nukaya, Haruo
CS Daiichi Suntory Biomedical Research Co., Ltd., Mishima-gun, Osaka, 618-8513, Japan
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3201-3203
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 141:106296
GI



I

AB The first total synthesis of structurally unique flavonoids I (R = OH, H) is described. These compds. showed very strong anti-inflammatory effect against delayed hypersensitivity in a mouse model.

IT 720684-57-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of fused tricyclic flavonoids from a D-glucal and their strong anti-inflammatory effect)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 720684-64-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused tricyclic flavonoids from a D-glucal and their strong anti-inflammatory effect)

RN 720684-64-0 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-8-[4-(phenylmethoxy)phenyl]-, (2R,3R,4S,4aR,11bS)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT